ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
- Mechanism
- Curator reviewed
Activation of dopamine D1 receptor in the brain is implicated in reward-seeking behaviours and cue-induced craving, and is the fundamental mechanism by which nicotine causes addiction. Both reward (the “feel good” sensation a smoker gets from a cigarette) and cue (the habitual situations that trigger the craving to smoke) are important drivers of the desire to smoke. Blocking the D1 receptor will, it is hoped, reduce the association with the stimuli specific to reward-seeking behaviour that lead smokers who are trying to quit starting smoking again.
- Primary indication
- Investigated for use/treatment in sleep disorders, smoking cessation, and substance abuse.Curator reviewed
- Formula / weight
- C19H20N2O4 · 340.379 g/mol (avg)
- Code names
- ADX-10061 · CEE 03-310 · CEE-310 · NNC 01-0687 · NNC-687 · NO 687
Resolves to
XZPSYCOYKJRHKE-MRXNPFEDSA-NSMILESCN1CCC2=CC(=C(O)C=C2[C@H](C1)C1=C2OCCC2=CC=C1)[N+]([O-])=OWhat you can answer from here — as of March 06, 2025
Which drugs share a target with ADX-10061, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account